CUREMARK CM-AT
A double-blind, randomized, placebo-controlled study of CM-AT for the treatment of autism in children with all levels of fecal chymotrypsin. Enrollment has closed.
About
A randomized, double-blind, placebo-controlled, parallel-group study is being done to test the efficacy, safety and tolerability of CM-AT vs. placebo in children (ages 3 to 8) with autism. Eligible participants will be in the study long term and will take the study drug three times daily with food. Enrollment has closed.
Eligibility Criteria
Inclusion Criteria
- Male or female 3–8 years old
- Diagnosis or symptoms of autism
Primary Investigator
Anita Kablinger, M.D., C.P.I.
Program Director of Clinical Trials Research with Carilion Clinic Psychiatry and Behavioral Medicine and Professor of Medicine at the Virginia Tech Carilion School of Medicine, with over 25 years clinical and research experience.
